Corline Biomedical (CLBIO) Stock Overview
Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CLBIO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Corline Biomedical AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 19.85 |
| 52 Week High | SEK 27.20 |
| 52 Week Low | SEK 5.98 |
| Beta | 0.27 |
| 1 Month Change | 32.33% |
| 3 Month Change | 54.47% |
| 1 Year Change | 119.09% |
| 3 Year Change | 121.05% |
| 5 Year Change | 14.74% |
| Change since IPO | 93.66% |
Recent News & Updates
Recent updates
Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business
Aug 24
We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth
Mar 15We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To Grow
Nov 26Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business
Jun 22We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business Growth
Feb 16Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In Growth
Jun 14Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn Situation
Feb 28Shareholder Returns
| CLBIO | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 36.4% | 2.2% | 2.7% |
| 1Y | 119.1% | 1.6% | -1.2% |
Return vs Industry: CLBIO exceeded the Swedish Pharmaceuticals industry which returned 1.6% over the past year.
Return vs Market: CLBIO exceeded the Swedish Market which returned -1.2% over the past year.
Price Volatility
| CLBIO volatility | |
|---|---|
| CLBIO Average Weekly Movement | 13.1% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.1% |
| 10% least volatile stocks in SE Market | 3.0% |
Stable Share Price: CLBIO's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: CLBIO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 13 | Henrik Nittmar | www.corline.se |
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company’s products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries.
Corline Biomedical AB Fundamentals Summary
| CLBIO fundamental statistics | |
|---|---|
| Market cap | SEK 486.14m |
| Earnings (TTM) | -SEK 23.48m |
| Revenue (TTM) | SEK 10.02m |
Is CLBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLBIO income statement (TTM) | |
|---|---|
| Revenue | SEK 10.02m |
| Cost of Revenue | SEK 3.14m |
| Gross Profit | SEK 6.89m |
| Other Expenses | SEK 30.37m |
| Earnings | -SEK 23.48m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 68.70% |
| Net Profit Margin | -234.29% |
| Debt/Equity Ratio | 0% |
How did CLBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 13:56 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Corline Biomedical AB is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gustaf Meyer | Redeye |